ELIE K. FRAIJI JR., M.D.

BEL AIR, MD

Research Active
Surgery NPI registered 21+ years 3 publications 2002 – 2003 NPI: 1669475869
Surgery
Case-Control StudiesLaparoscopyHernia, HiatalRecurrenceBiopsy, NeedleCombined Modality TherapyPalliative CareMinimally Invasive Surgical ProceduresCatheterizationGastroesophageal RefluxEsophageal AchalasiaFundoplicationBotulinum Toxins, Type ADiverticulum, EsophagealHeartburn

Practice Location

520 UPPER CHESAPEAKE DR
BEL AIR, MD 21014-4381

Phone: (443) 643-4400

What does ELIE FRAIJI research?

Dr. Fraiji studies treatments for achalasia, a condition that makes it difficult for people to swallow due to problems with the esophagus. He explores various surgical options, like laparoscopic Heller myotomy, which helps relieve symptoms such as swallowing difficulties and heartburn. In addition, he investigates treatment strategies for advanced liver cancer, using methods like transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) to prolong survival and improve quality of life for patients who cannot undergo surgery.

Key findings

  • Patients with achalasia showed significant improvement in swallowing difficulty, with scores decreasing from 4.5 to 1.8 after laparoscopic esophageal diverticulectomy.
  • Heartburn symptoms in achalasia patients improved from an average score of 4.3 to 1.3 after laparoscopic surgery.
  • In patients with liver cancer, those treated with both TACE and RFA had a one-year survival rate of 100%, while the rate was 67% for those treated with TACE alone.

Frequently asked questions

Does Dr. Fraiji study achalasia?
Yes, Dr. Fraiji conducts research on achalasia and its surgical treatments to help improve swallowing and reduce symptoms.
What treatments has Dr. Fraiji researched for liver cancer?
Dr. Fraiji has researched the combination of transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) as effective treatments for advanced liver cancer.
Is Dr. Fraiji's work relevant to patients with swallowing difficulties?
Absolutely, his studies focus specifically on helping patients suffering from swallowing difficulties due to conditions like achalasia.

Publications in plain English

Preoperative intervention does not affect esophageal muscle histology or patient outcomes in patients undergoing laparoscopic Heller myotomy.

2003

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract

Bloomston M, Fraiji E, Boyce HW, Gonzalvo A, Johnson M +1 more

Plain English
This study looked at whether treatments like Botox and pneumatic dilation before surgery affect the condition of esophageal muscles or patient recovery for people with a swallowing disorder called achalasia who underwent laparoscopic Heller myotomy. Researchers found that these pre-surgery treatments didn't change the muscle's condition or improve outcomes; however, patients did see significant relief in swallowing difficulties (from a score of 4.5 to 1.6) and heartburn (from 2.3 to 1.5) after the surgery. Overall, 92% of patients reported good results after about 16 months, showing that laparoscopic Heller myotomy is likely effective no matter what treatment was given before. Who this helps: Patients suffering from achalasia.

PubMed

Laparoscopic management of symptomatic achalasia associated with epiphrenic diverticulum.

2003

Surgical endoscopy

Fraiji E, Bloomston M, Carey L, Zervos E, Goldin S +3 more

Plain English
This study looked at a surgical procedure called laparoscopic esophageal diverticulectomy, combined with a myotomy and partial fundoplication, to treat patients suffering from achalasia and epiphrenic diverticula. The results showed that patients' difficulty swallowing (dysphagia) improved significantly, from an average score of 4.5 to 1.8, and heartburn symptoms also decreased from 4.3 to 1.3 after the surgery, indicating effective relief of their symptoms. This research is important because it shows a safe and effective way to help patients with these conditions feel better and improve their quality of life. Who this helps: This helps patients suffering from achalasia and esophageal diverticula.

PubMed

Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy.

2002

The American surgeon

Bloomston M, Binitie O, Fraiji E, Murr M, Zervos E +6 more

Plain English
This study looked at a treatment approach for patients with advanced liver cancer using two methods: transcatheter arterial chemoembolization (TACE) alone and TACE combined with radiofrequency ablation (RFA). It found that patients who received both treatments had a much better outcome, with a one-year survival rate of 100% compared to 67% for those who only had TACE. Additionally, the average survival for those receiving both treatments was 25.3 months, while it was only 11.4 months for the TACE-only group. Who this helps: This helps patients with liver cancer who are not eligible for surgery.

PubMed

Frequent Co-Authors

Mark Bloomston Alexander S Rosemurgy M Bloomston L Carey E Zervos S Goldin M Banasiak M Wallace A S Rosemurgy H Worth Boyce

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.